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Abstract
Background: Family support and patient satisfaction with treatment are crucial for aiding in the recovery from
stroke. However, current validated stroke-specific questionnaires may not adequately capture the impact of these
two variables on patients undergoing clinical trials of new drugs. Therefore, the aim of this study was to develop
and evaluate a new stroke patient-reported outcome measure (Stroke-PROM) instrument for capturing more
comprehensive effects of stroke on patients participating in clinical trials of new drugs.
Methods: A conceptual framework and a pool of items for the preliminary Stroke-PROM were generated by
consulting the relevant literature and other questionnaires created in China and other countries, and interviewing
20 patients and 4 experts to ensure that all germane parameters were included. During the first item-selection
phase, classical test theory and item response theory were applied to an initial scale completed by 133 patients
with stroke. During the item-revaluation phase, classical test theory and item response theory were used again, this
time with 475 patients with stroke and 104 healthy participants. During the scale assessment phase, confirmatory
factor analysis was applied to the final scale of the Stroke-PROM using the same study population as in the second
item-selection phase. Reliability, validity, responsiveness and feasibility of the final scale were tested.
Results: The final scale of Stroke-PROM contained 46 items describing four domains (physiology, psychology, society
and treatment). These four domains were subdivided into 10 subdomains. Cronbach’s α coefficients for the four
domains ranged from 0.861 to 0.908. Confirmatory factor analysis supported the validity of the final scale, and the
model fit index satisfied the criterion. Differences in the Stroke-PROM mean scores were significant between patients with
stroke and healthy participants in nine subdomains (P < 0.001), indicating that the scale showed good responsiveness.
Conclusions: The Stroke-PROM is a patient-reported outcome multidimensional questionnaire developed especially for
clinical trials of new drugs and is focused on issues of family support and patient satisfaction with treatment. Extensive
data analyses supported the validity, reliability and responsiveness of the Stroke-PROM.
Keywords: Stroke, Patient-reported outcome, Item response theory, Classical test theory, Confirmatory factor analysis,
Reliability, Validity, Measurement
Background
Stroke is the second leading cause of mortality world-
wide [1], and stroke survivors are often severely disabled
for the rest of their lives [2]. More than 85% of strokes
occur in developing countries [3]. Epidemiological sur-
veys have shown that there are 150–200 million new
cases of stroke each year in China. The age-adjusted
annual incidence rate of stroke is 116–219 per 100,000
people, and the annual mortality rate from stroke is
58–142 per 100,000 people [4].
Stroke has considerable adverse physical and psycho-
logical impacts on patients over time [5,6]. For the diag-
nosis and treatment of stroke and its sequelae, therefore,
purely objective indicators do not accurately measure
the multifaceted impact of stroke on patients. Assess-
ment of the effects of treatment on any individual pa-
tient should include the patient’s own evaluation of
therapy, or patient-reported outcome (PRO) [7]. A PRO
is any report of the status of a patient’s health condition* Correspondence: sxmuzyb@126.com
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that comes directly from the patient, without interpret-
ation of the patient’s response by a clinician or anyone
else [8,9].
In recent years, multiple measures, including generic
and disease-specific measures, have been used to assess
outcomes of patients with stroke. Generic instruments
are useful for comparing quality of life impact in popula-
tions with different diseases; however, disease-specific
tools are generally more responsive and sensitive to
disease-specific issues and are therefore more appropri-
ate for clinical trials in which specific therapeutic inter-
ventions are being evaluated [10,11]. Although PRO
tools developed specifically for stroke do exist (e.g.,
Newcastle Stroke-Specific Quality of Life Measure;
Stroke and Aphasia Quality of Life Scale-39 item ver-
sion; Stroke Impact Scale version 2.0), a review of these
instruments yielded no measure that captures PRO asso-
ciated with family support and patient satisfaction with
treatment, two particularly significant issues for many
stroke survivors [12-15]. Given the absence of stroke-
specific measures in the subdomains of family support
and treatment satisfaction, the development is necessary
of a more comprehensive multidimensional scale that
evaluates all facets of the health status in patients with
stroke.
Therefore, the aim of this study was to develop an
understandable, reliable and valid PRO measure for pa-
tients with stroke that captures valuable data from the
patient’s viewpoint. This article reports on the develop-
ment of the initial pool of items, selection of the final




The study protocol and the Stroke-PROM were reviewed
and approved by the Medical Ethics Committee of
Shanxi Medical University. Participants signed informed
consent forms prior to study participation, and all were
compensated for their time.
Study population and design
Patients were enrolled from nine different hospitals,
communities, and rural areas in Shanxi province in
China. Clinical investigators at all study sites recruited
participants using the International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD-9-
CM). Patients participating in this study were diagnosed
with stroke by a physician and were not in the acute
phase of stroke. The severity of poststroke sequelae in
these patients varied from mild to severe. Individuals
with tetraplegia, psychosis, or serious comorbidities (e.g.,
cancer) were excluded. Control participants were re-
cruited from lists of patients who did not have cerebral
vascular disease, cancer, or mental illness. Investigators
helped patients with severe visual impairments fill in the
questionnaires according to the patients’ verbal re-
sponses to items.
Ten patients with stroke were interviewed to identify
potential items for use in the questionnaire. Five patients
with stroke, three physician experts in stroke and one
psychometric expert were interviewed for item revision
and refinement to ensure that all items were appropriate
and relevant. Five stroke patients were interviewed to
evaluate their comprehension of each item. For the first
item pool reduction, 135 patients with stroke were re-
cruited from nine different hospitals, communities, and
rural areas in Shanxi province; valid data from 133 par-
ticipants were collected. For the item-revaluation phase
and the validation phase of the Stroke-PROM, 485 pa-
tients with stroke and 110 controls from the same nine
geographical regions were recruited, but only 475 and
104, respectively, were available to participate in the
study. There was no overlap in the participants who
contributed to the first and second item-reduction pro-
cesses [16,17].
Development of the Stroke-PROM
The Stroke-PROM was developed in four phases: (1)
conceptual framework construction and preliminary
item generation; (2) formation of the initial scale by the
first item-selection process; (3) formation of the final
scale by an item-revaluation process based on the sec-
ond item-selection process; and (4) validation of the
Stroke-PROM. Phase 1 involved a qualitative analysis,
whereas the other three phases used quantitative ana-
lyses. A flowchart of this four-phase developmental
process is shown in Figure 1.
Identifying the conceptual framework and preliminary
item content
A comprehensive review of existing stroke questionnaires
was performed to identify an appropriate conceptual
framework (see Figure 2). Four domains and 10 subdo-
mains were generated. In-depth open-ended interviews of
10 stroke patients (5 men and 5 women; ages: ≤45, n = 2;
45–65, n = 5; ≥65, n = 3) were conducted to identify po-
tential items for the Stroke-PROM using the selected con-
ceptual framework. Patients were interviewed about their
symptoms, their main psychological burden, the effects of
stroke on them and their families, and their evaluations of
the therapeutic effect and medical workers. As a result, a
bank of 62 potential items was generated. Four chief phy-
sicians and five patients (3 men and 2 women; ages: ≤45,
n = 1; 45–65, n = 2; ≥65, n = 2; education: high school de-
grees or above), all of whom were recruited from the First
Hospital of Shanxi Medical University and Second Hos-
pital of Shanxi Medical University, participated in revising
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these 62 preliminary items using a content validity
index (CVI) (62 items and scale structure described in
Additional file 1: Appendices 1–1 and 1–2).
The CVI is widely used for quantifying content valid-
ity for scales. Item-level CVI (I-CVI) is calculated by
having experts rate the relevance of each item to its
own subdomain (1 = not relevant, 2 = somewhat rele-
vant, 3 = quite relevant, 4 = highly relevant). The I-CVI
of each item is defined as the number of experts offer-
ing a rating of 3 or 4, divided by the number of
experts.
As an adjustment for chance agreements, the multi-







where Pc is the probability of chance agreement, n is
the number of experts, and A is the number approving
with good relevance. K* was calculated using the I-CVI
and the probability of chance agreement as follows:
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Generation of final scale
Note: CVI, content validity index; CTT, classical test theory; IRT, item response theory; SD, Standard 
Deviation; CAID, Cronbach’s α if item deleted; CITC, corrected item-total correlation.
Figure 1 Flowchart of the Stroke-PROM developmental process. Note: CVI, content validity index; CTT, classical test theory; IRT, item response theory; SD,

















Figure 2 Conceptual framework of the Stroke-PROM.
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k ¼ I−CVI−Pc
1−Pc
Each item on the scale was then rated as “fair,”
“good,” or “excellent,” based on the following rating
criteria: fair, K* = 0.40–0.59; good, K* = 0.60–0.74; excel-
lent, K* > 0 .74. Any item that received a “fair” rating
was deleted.
Five participants with stroke (2 men, 3 women; ages: ≤45,
n = 1; 45–65, n = 2; ≥65, n = 2) were interviewed to evaluate
their comprehension of each item. Items that were ambigu-
ous, misunderstood, or rarely answered were reworded.
The preliminary scale was developed after modifying the
item pool based on the suggestions of the physician experts,
psychometric expert and patients as well as on the out-
comes of the comprehension tests for patients. In the end,
the preliminary tool included 4 domains, 11 subdomains,
and 60 items.
Formation of the initial scale
One hundred thirty-three patients were told that the
aim of the questionnaire was to measure how much
their stroke had affected them. For each issue presented
in an item, patients responded using a five-point Likert
scale to reflect how often they experienced the issue,
where 0 = never, 1 = occasionally, 2 = about half of the
time, 3 = often, and 4 = always. Scores of positively
worded items were recoded as the original score plus 1,
whereas scores of negatively worded items were recoded
as 5 minus the original response. This recoding pro-
duced a score range for each item of 1 to 5, with a
higher score reflecting a more positive PRO.
The item-reduction processes of the preliminary scale
were based on both classical test theory (CTT) (e.g.,
discrete trend, factor analysis, correlation coefficient,
Cronbach’s α if item deleted [CAID] values, and cor-
rected item-total correlation [CITC]) and item response
theory (IRT). CTT was used to reduce the number of
items of the Stroke-PROM in the first four of the follow-
ing steps, and IRT was used in the fifth step.
In step 1, the standard deviation in the score for every
item was calculated. A low standard deviation indicates
a low degree of differentiation and should be removed;
thus, those items with a low standard deviation (<0.96)
were deleted in this study.
In step 2, a principal component factor analysis with
varimax rotation aided in item reduction. The value for
the Kaiser–Meyer–Olkin measure of sampling adequacy
was >0.5 [17]. Items with low factor loading (<0.4) or
items with factor loading close to other factors was
considered for removal.
In step 3, an item was considered for deletion when
the Pearson correlation coefficient between the item and
its own subdomain was <0.6, which indicated that the
item did not represent the subdomain well.
In step 4, the internal consistency of items was evalu-
ated using the CITC and CAID values. An item was
considered to have highly contributed to the measured
construct when the CITC value was more than 0.45. The
CAID value also determines which item highly contrib-
utes to the reliability of the Stroke-PROM. An increase
in the CAID value indicates that the items poorly con-
tribute to Cronbach’s α value and should be deleted.
Therefore, an item was deleted in the present study
when the CITC value was <0.45 and the CAID value
increased [20-22].
In step 5, IRT was applied to reduce the number of
items in the Stroke-PROM. Each item’s parameters of
discrimination (α) and difficulty (b) were estimated.
Generally, items with discrimination values <0.4 should
be deleted. The value of the four degrees of difficulty
(b1, b2, b3, b4) ranged from −3 to 3. Items with degrees
of difficulty (b1, b2, b3, b4) values outside the range of −3
to 3 should be considered for removal [23].
Both the statistical results and clinical relevance of
items were also taken into account prior to an item’s
deletion. The resulting initial scale resulted from the
removal of items from the preliminary scale.
Formation and validation of the final scale
Thus, an initial scale was generated following the evalu-
ation and selection of items from the preliminary scale.
To ensure the reliability and validity of each item in-
cluded in this initial Stroke-PROM, the items were re-
evaluated based on a second item-selection of the initial
scale. The CTT and IRT were applied once again to re-
evaluate the items in the initial Stroke-PROM using the
data gathered from 475 stroke patients, generating the
final scale. The final Stroke-PROM tool was then evalu-
ated for validity, reliability, and responsiveness using the
data obtained from these 475 stroke patients as well as
104 control participants.
Content validity
Content validity was achieved by referring to relevant lit-
erature, consulting questionnaires from China and other
countries, interviewing 10 patients to identify potential
items, and consulting with 5 patients, 3 physician ex-
perts and 1 psychometric expert for item revision and
refinement to ensure that all items were appropriate and
relevant. Content validity was confirmed using the CVI.
Construct validity
Confirmatory factor analysis with the index of model fit
was performed to investigate the factor structure of the
scale [23]. The model indicates a good fit when the
goodness-of-fit index (GFI), normed fit index (NFI),
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non-normed fit index (NNFI), incremental fit index (IFI)
and comparative fit index (CFI) are all >0.9, and the root
mean square residual (RMR) is <0.09. GFI, RMR, NFI
and CFI range from 0 to 1.
Reliability
Cronbach’s α coefficients for the four domains and the
total scale were calculated to measure the internal
consistency of the Stroke-PROM. Generally a Cronbach’s
α coefficient ≥ 0.7 indicates an acceptable level of in-
ternal consistency.
Discriminant validity
The modified Rankin Scale, a frequently used scale for
measuring the degree of disability and dependence in
the daily activities of people who have had a stroke, was
used as the stroke outcome measure in the present
study. This ordered scale ranges from 0 (no symptoms)
to 5 (severe disability). Discriminant validity was
assessed by comparing the mean scores for every subdo-
main of the Stroke-PROM among healthy participants
with those among groups of stroke patients as defined
by the Rankin scale, except for the subdomain of treat-
ment. The comparison of means was performed using
analysis of variance, with the significance level set at p <
0.05. The rejection of the null hypothesis would indicate
that the scale has the ability to differentiate between
healthy controls and stroke patients with varying degrees
of disability and dependence as defined by the modified
Rankin scale.
Feasibility
The feasibility of the Stroke-PROM tool was evaluated
by examining the response rate, completion rate and re-
sponse time to completion. Response and return rates
above 95% were deemed adequate, and completion times
of 8 to 13 minutes were considered acceptable.
Data analysis software
Data analyses were conducted using SPSS 13.0, Multilog
7.03 and LISREL 8.70 software.
Results
Participant characteristics
Tables 1 and 2 show the characteristics of the 133 pa-
tients with stroke who completed the preliminary scale
and of the 475 stroke patients and 104 control partici-
pants who completed the initial scale.
The demographic characteristics of the participants
shown in Tables 1 and 2 indicated that the stroke sample
population consisted of more men than women, more
than 75% of all participants were over 45 years of age,
and more than 80% were married. Additionally, approxi-
mately 70% of all participants had junior high school
education or less. Table 2 shows that the proportion of
males with stroke was a little higher than that of healthy
males, and that among participants over 65 years old,
the proportion of stroke patients was slightly higher than
that of healthy participants. The average length of time
since stroke diagnosis was approximately 6.3 months
Table 1 Demographic characteristics of 133 patients with









Marital status (n (%))
Married 114 (85.7)
Unmarried, divorce or widowed 19 (14.3)
Highest education level completed (n (%))
Primary school or lower 53 (39.8)
Junior high school 45 (33.8)
Senior high school 19 (14.3)
College or higher 16 (12.0)
Table 2 Demographic characteristics of 475 stroke
patients and 104 controls in the second item-selection





Male 283 (59.6) 49 (47.1) 5.418 0.020
Female 192 (40.4) 55 (52.9)
Age (n (%))
≤45 55 (11.6) 24 (23.1) 13.626 0.001
45–65 230 (48.4) 54 (51.9)
≥65 190 (40.0) 26 (25.0)
Marital status (n (%))
Married 398 (83.8) 86 (82.7) 0.075 0.784
Unmarried, divorced or
widowed
77 (16.2) 18 (17.3)
Highest education level
completed (n (%))
Primary school or lower 183 (38.5) 43 (41.3) 2.870 0.412
Junior high school 144 (30.3) 37 (35.6)
Senior high school 88 (18.5) 15 (14.4)
College or higher 60 (12.6) 9 (8.7)
Luo et al. Health and Quality of Life Outcomes  (2015) 13:53 Page 5 of 18
Table 3 Content validity index based on grade of patients and experts of preliminary Stroke-PROM






A B C D A B C D E
PHD 1 3 4 4 4 3 4 4 4 3 9 1.00 0.002 1.00 excellent
PHD 2 3 4 4 3 3 4 4 4 3 9 1.00 0.002 1.00 excellent
PHD 3 2 3 3 2 2 3 3 4 2 5 0.56 0.246 0.42 fair
PHD 4 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PHD 5 2 2 2 1 2 3 3 2 2 2 0.22 0.070 0.16 fair
PHD 6 2 3 2 2 2 2 3 2 1 2 0.22 0.070 0.16 fair
PHD 7 3 4 4 3 4 4 4 4 3 9 1.00 0.002 1.00 excellent
PHD 8 3 4 4 4 3 4 4 4 4 9 1.00 0.002 1.00 excellent
PHD 9 2 2 3 3 2 2 3 3 1 4 0.44 0.246 0.26 fair
PHD 10 1 2 1 2 2 2 3 2 2 1 0.11 0.018 0.09 fair
PHD 11 1 2 1 1 2 2 3 2 1 1 0.11 0.018 0.09 fair
PHD 12 3 4 3 4 4 4 4 3 2 8 0.89 0.014 0.89 excellent
PHD 13 3 2 3 4 3 4 3 3 2 7 0.78 0.070 0.76 excellent
PHD 14 3 4 4 3 3 4 3 3 2 8 0.89 0.014 0.89 excellent
PHD 15 3 4 3 3 3 3 4 4 4 9 1.00 0.002 1.00 excellent
PHD 16 3 3 2 3 2 2 3 4 4 6 0.67 0.164 0.61 good
PHD 17 3 4 4 4 4 4 4 3 4 9 1.00 0.002 1.00 excellent
PHD 18 3 4 2 4 3 3 4 2 4 7 0.78 0.070 0.76 excellent
PHD 19 3 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PHD 20 3 3 3 4 4 4 3 4 4 9 1.00 0.002 1.00 excellent
PHD 21 3 2 4 4 4 4 4 4 3 8 0.89 0.014 0.89 excellent
PHD 22 3 3 3 3 4 3 3 4 3 9 1.00 0.002 1.00 excellent
PHD 23 3 4 4 4 4 4 4 4 3 9 1.00 0.002 1.00 excellent
PSD1 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD2 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD3 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD4 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD5 4 4 4 4 3 4 4 4 3 9 1.00 0.002 1.00 excellent
PSD6 4 4 4 4 3 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD7 3 4 4 4 3 3 4 4 4 9 1.00 0.002 1.00 excellent
PSD8 3 4 4 4 3 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD9 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD10 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD11 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD12 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD13 3 4 3 4 3 4 4 4 3 9 1.00 0.002 1.00 excellent
PSD14 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD15 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD16 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD17 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
PSD18 3 4 4 2 3 4 4 3 3 8 0.89 0.014 0.89 excellent
PSD19 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
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and 7.2 months for patients in the first item pool reduc-
tion phase, and the revaluation and validation phases,
respectively.
Item generation
Four domains, 10 subdomains and a pool of 62 items
were generated for the Stroke-PROM based on consult-
ing relevant literature, examining other questionnaires,
and interviewing 10 patients to ensure that all germane
topics were included. The items and construction of the
Stroke-PROM tool are described in Additional file 1:
Appendices 1–1 and 1–2.
Four chief physicians and five patients (distinguished
by different letters of the alphabet) who had attained a
high school degree or above participated in the revision
of the 62 items of the Stroke-PROM by rating the items
according to the CVI (see Table 3).
On the basis of the CVI results, advice from patients
and experts, and the clinical relevance of items, seven
items (item PHD3, PHD5, PHD6, PHD9, PHD16, PSD18
and SOD1 shown in Additional file 1: Appendix 1-1)
were deleted, and the subdomain of cognition was
added. Items PHD10 and PHD11 shown in Additional
file 1: Appendix 1-1 were retained based on the advice
of patients and experts and other stroke-specific scales.
These two items were assimilated into the newly added
cognitive subdomain. The following five items were also
added: Have you felt any limb abnormalities [such as a
burning sensation]?; Do your hands tremble when you
reach for or pick up things?; Do you have trouble remem-
bering the date?; When you see an object suddenly, do
you struggle to bring its name to mind?; When others
talk about your disease, do you prefer not to discuss it?
(PHD2, PHD7, PHD10, PHD11 and PSD18 shown in
Additional file 1: Appendix 2-1) [13-15]. The CVI values
of the five added items were calculated, the K* values of
the five added items were all >0.74, and the five added
items were rated “excellent.”
Five stroke patients of varying educational levels were
interviewed to evaluate their comprehension of each
item. Items that were ambiguous, misunderstood or
rarely answered were reworded using comprehension
tests for patients with stroke. The preliminary scale was
developed after modifying the item pool based on the
advice of the experts and the outcomes of the compre-
hension tests. The preliminary scale included 4 domains,
11 subdomains and 60 items. The items were also reor-
dered (see Additional file 1: Appendices 2–1 and 2–2).
Item reduction
The two-step item selection process is described in
Tables 4 and 5. This iterative process resulted in a
Table 3 Content validity index based on grade of patients and experts of preliminary Stroke-PROM (Continued)
PSD20 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
SOD1 2 4 3 2 2 3 4 4 2 5 0.56 0.246 0.42 fair
SOD2 3 4 4 3 3 3 4 4 3 9 1.00 0.002 1.00 excellent
SOD3 3 4 4 4 3 4 4 4 3 9 1.00 0.002 1.00 excellent
SOD4 3 4 4 2 3 4 4 4 3 8 0.89 0.014 0.89 excellent
SOD5 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
SOD6 3 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
SOD7 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
SOD8 3 4 4 4 3 4 4 4 4 9 1.00 0.002 1.00 excellent
SOD9 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
SOD10 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
THD1 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
THD2 3 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
THD3 3 4 4 4 3 4 4 4 3 9 1.00 0.002 1.00 excellent
THD4 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
THD5 4 4 4 4 4 4 4 4 4 9 1.00 0.002 1.00 excellent
THD6 4 4 4 4 3 4 4 4 4 9 1.00 0.002 1.00 excellent
THD7 3 4 4 4 3 4 4 4 3 9 1.00 0.002 1.00 excellent
THD8 2 4 4 4 3 4 4 4 3 8 0.89 0.014 0.89 excellent
THD9 3 4 4 4 2 3 4 4 2 7 0.78 0.070 0.76 excellent
Note: Letters A to D represent individual experts; letters A to E represent individual patients; 1 = not relevant, 2 = somewhat relevant, 3 = quite relevant, 4 = highly
relevant; CVI, content validity index; I-CVI, Item-level CVI; K*, the multi-rater kappa statistic; PHD, physical domain; PSD, psychological domain; SOD, social domain;
THD, therapeutic domain.
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CITC CAID IRT Outcome
α b1 b2 b3 b4
PHD1 1.464 0.752 0.784 0.705 0.908 0.88 −1.67 −0.37 0.09 1.72 √
PHD2 1.423 0.706 0.763 0.712 0.906 1.13 −1.85 −0.39 −0.12 1.16 √
PHD3 1.446 0.799 0.811 0.77 0.900 1.30 −1.44 −0.78 −0.32 0.36 √
PHD4 1.355 0.734 0.822 0.739 0.903 1.26 −1.16 −0.10 0.61 1.97 √
PHD5 1.320 0.845 0.799 0.825 0.894 1.59 −1.78 −0.71 −0.34 0.25 √
PHD6 1.246 0.811 0.758 0.768 0.901 1.29 −2.20 −0.93 −0.22 0.77 √
PHD7 1.213 0.722 0.743 0.689 0.908 1.57 −1.90 −0.72 0.03 0.98 √
PHD8 1.439 0.781 0.835 0.628 0.869 0.53 −3.23 −1.31 −0.32 1.77 X
PHD9 1.325 0.777 0.818 0.697 0.836 1.18 −1.98 −0.70 −0.10 1.05 √
PHD10 1.266 0.801 0.802 0.777 0.804 1.29 −1.71 −0.97 −0.49 0.95 √
PHD11 1.214 0.745 0.813 0.779 0.806 1.63 −1.89 −0.89 −0.37 0.49 √
PHD12 1.395 0.473 0.657 0.515 0.694 1.37 −1.62 −0.58 −0.38 0.50 √
PHD13 1.310 0.514 0.664 0.584 0.659 1.15 −1.89 −1.11 −0.53 0.61 √
PHD14 1.520 0.489 0.793 0.478 0.718 0.29 −4.94 −2.28 −0.60 2.39 √
PHD15 1.471 0.549 0.748 0.573 0.661 0.30 −5.24 −4.20 −2.91 0.52 √
PHD16 1.582 0.786 0.739 0.634 0.789 0.47 −2.40 −1.77 −1.07 1.19 √
PHD17 1.500 0.779 0.740 0.676 0.782 0.37 −3.83 −2.92 −1.87 0.97 √
PHD18 0.930 0.081 0.405 0.208 0.843 0.90 −4.18 −2.86 −2.25 −1.15 X
PHD19 1.535 0.262 0.495 0.299 0.843 0.74 −2.40 −0.3 0.13 1.01 X
PHD20 1.756 0.709 0.789 0.643 0.787 0.87 −0.31 0.16 0.47 1.27 √
PHD21 1.654 0.815 0.786 0.736 0.769 0.70 −1.28 −0.76 −0.30 0.93 √
PHD22 1.566 0.865 0.785 0.753 0.767 0.72 −1.69 −1.01 −0.48 0.87 √
PSD1 1.387 0.718 0.769 0.66 0.828 1.00 −1.64 −0.29 0.24 0.94 √
PSD2 1.413 0.784 0.735 0.584 0.840 1.00 −1.41 −0.11 0.32 2.03 √
PSD3 1.370 0.641 0.761 0.626 0.833 1.43 −1.34 −0.16 0.15 1.49 √
PSD4 1.264 0.679 0.750 0.704 0.822 1.76 −1.60 −0.63 −0.26 0.85 √
PSD5 1.237 0.407 0.565 0.474 0.854 1.85 −1.35 −0.73 −0.35 0.87 X
PSD6 1.319 0.566 0.697 0.592 0.838 1.58 −1.38 −0.12 0.23 1.65 √
PSD7 1.230 0.595 0.706 0.696 0.824 1.80 −1.37 −0.63 −0.18 1.15 √
PSD8 1.317 0.652 0.511 0.439 0.902 0.99 −2.09 −1.10 −0.60 1.06 X
PSD9 1.022 0.727 0.614 0.502 0.893 1.11 −3.83 −1.93 −1.30 −0.05 X
PSD10 1.183 0.648 0.692 0.695 0.876 1.71 −1.83 −0.85 −0.60 0.65 √
PSD11 1.106 0.600 0.640 0.651 0.881 1.68 −2.15 −1.15 −0.62 0.70 √
PSD12 1.198 0.816 0.853 0.795 0.866 2.33 −1.51 −0.76 −0.19 0.83 √
PSD13 1.271 0.791 0.778 0.755 0.870 2.90 −1.32 −0.30 0.05 0.87 √
PSD14 1.288 0.845 0.810 0.777 0.868 2.43 −1.57 −0.60 −0.18 0.48 √
PSD15 1.200 0.820 0.776 0.766 0.869 2.80 −1.45 −0.72 −0.17 0.58 √
PSD16 1.128 0.551 0.724 0.609 0.645 1.91 −2.35 −0.99 −0.35 0.50 √
PSD17 1.215 0.589 0.706 0.632 0.631 1.86 −1.71 −0.87 −0.44 0.62 √
PSD18 1.321 0.441 0.721 0.472 0.695 1.13 −2.43 −0.77 −0.30 0.85 √
PSD19 1.222 0.515 0.655 0.485 0.689 1.61 −1.60 −1.02 −0.59 0.60 √
PSD20 1.310 0.325 0.528 0.305 0.759 0.73 −3.44 −1.53 −1.08 0.63 X
SOD1 1.403 0.658 0.578 0.382 0.776 0.72 −1.68 −0.04 1.14 2.59 X
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final version that comprised 46 items within 10 subdo-
mains. (The deletion of the compliance subdomain is
explained in the next section.) Each subdomain was
named according to its constituent items.
First item-selection phase based on CTT and IRT
Five statistical methods (within CTT and IRT) were used
to select items. Any item recommended for deletion by
two or more methods was deleted. All items were de-
leted or added based on their item selection results,
their clinical importance, and other stroke-specific
scales (see Table 4).
As seen in Table 4, 12 items were removed; however,
PHD8 (Do you remember what happened two days ago?)
was not deleted, because previously published results
indicate that this item is crucial for the assessment of
cognition [15]. PSD1 (Are you more prone to worry since
your illness?) and PSD2 (Do you get angry easily?) did
not discriminate well, so PSD2 was deleted in accord
with the opinion of patients and experts. PSD15 (Have
you felt depressed while in a cheerful atmosphere?) was
deleted because it was not deemed closely relevant to
stroke. As a result, 13 items (PHD18, PHD19, PSD2,
PSD5, PSD8, PSD9, PSD15, PSD20, SOD1, SOD2,
THD1, THD2, THD3; Additional file 1: Appendix 2-1 )
were deleted. All items in the compliance subdomain
(THD1, THD2, THD3) were deleted; thus, this subdo-
main was also deleted [13-15].
Therefore, the initial scale contained 47 items, 10 sub-
domains, and 4 domains (see Appendices 3–1 and 3–2).
Revaluation phase based on CTT and IRT
To ensure the reliability and validity of each item in-
cluded in the initial scale, we revaluated the items in this
scale based on a second item selection. The evaluation
results suggested that all items were perfect, except for
item THD3. Thus, CTT and IRT analyses in the revalu-
ation phase led to deletion of item THD3 (Are you satis-
fied with your medical expenses?) (see Table 5). As a
result, the final scale contained 46 items, 10 subdomains,
4 domains (see Tables 6 and 7). This revision of the
Stroke-PROM is described in Table 8.
Evaluation of the scale
The validity, reliability, and responsiveness of the
remaining 46 items were assessed and the results are
presented in the sections below.
Content validity
The content validity was achieved as outlined in the
Methods and was confirmed using the values obtained
for the CVIs (see Table 3 and “Item generation” in the
Results).
Construct validity
We conducted confirmatory factor analysis (CFA) on the
46 Stroke-PROM items. The index of fit (GFI, RMR,
Table 4 Results of the first item-selection phase using CTT and IRT (Continued)
SOD2 1.495 0.221 0.594 0.327 0.797 0.86 −1.86 −0.71 0.10 1.06 X
SOD3 1.502 0.632 0.761 0.580 0.709 1.07 −1.58 −0.34 0.35 1.04 √
SOD4 1.384 0.728 0.869 0.751 0.649 1.56 −1.47 −0.36 0.16 0.97 √
SOD5 1.365 0.651 0.800 0.701 0.669 1.88 −1.55 −0.45 0.01 0.62 √
SOD6 1.608 0.835 0.867 0.614 0.694 0.20 −4.51 −3.13 −2.34 3.21 √
SOD7 1.205 0.695 0.705 0.573 0.718 0.37 −6.67 −3.95 −3.14 1.58 √
SOD8 1.589 0.765 0.849 0.612 0.694 0.27 −3.91 −2.27 −1.66 2.69 √
SOD9 1.114 0.619 0.610 0.526 0.742 0.50 −5.02 −4.03 −2.72 1.34 √
THD1 0.961 0.362 0.650 0.304 0.451 0.39 −8.45 −6.33 −4.91 −0.72 X
THD 2 1.348 0.512 0.772 0.413 0.232 0.38 −6.18 −3.55 −1.78 −0.47 X
THD3 1.438 0.500 0.743 0.277 0.501 0.38 −5.01 −0.74 0.64 2.52 X
THD 4 1.265 0.585 0.694 0.495 0.835 0.37 −6.29 −3.13 −1.75 2.30 √
THD 5 1.090 0.741 0.753 0.643 0.807 0.56 −5.18 −3.67 −1.61 1.13 √
THD 6 1.299 0.732 0.785 0.662 0.801 0.55 −4.09 −2.25 −0.90 1.30 √
THD 7 1.440 0.716 0.751 0.574 0.823 0.33 −4.23 −0.36 1.31 4.26 √
THD 8 1.111 0.833 0.804 0.728 0.792 0.45 −8.11 −3.77 −1.71 1.14 √
THD 9 1.242 0.748 0.745 0.619 0.810 0.62 −3.61 −2.49 −1.06 1.23 √
Note: CTT, classical test theory; IRT, item response theory; SD, Standard Deviation; CITC, corrected item-total correlation; CAID, Cronbach’s α if item deleted; PHD,
physical domain; PSD, psychological domain; SOD, social domain; THD, therapeutic domain; "√" decision to retain the selected item, "X" to delete the item;
boldface indicates values that did not meet standard.
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CITC CAID IRT Outcome
α b1 b2 b3 b4
PHD1 1.526 0.745 0.685 0.527 0.777 0.54 −2.65 −1.22 −0.31 1.40 √
PHD2 1.467 0.805 0.638 0.473 0.786 0.68 −2.59 −1.11 −0.36 1.06 √
PHD3 1.543 0.643 0.658 0.488 0.785 0.88 −0.94 −0.06 0.71 1.80 √
PHD4 1.350 0.659 0.687 0.551 0.771 1.14 −2.08 −1.18 −0.62 0.22 √
PHD5 1.230 0.828 0.726 0.616 0.762 1.30 −2.33 −1.37 −0.73 −0.19 √
PHD6 1.218 0.818 0.671 0.547 0.773 1.00 −2.79 −1.61 −0.72 0.58 √
PHD7 1.293 0.628 0.686 0.557 0.771 1.02 −2.51 −1.45 −0.46 0.44 √
PHD8 1.282 0.784 0.805 0.637 0.710 1.14 −2.23 −1.17 −0.31 0.77 √
PHD9 1.314 0.737 0.812 0.642 0.706 1.27 −1.84 −0.87 −0.12 0.92 √
PHD10 1.230 0.666 0.777 0.602 0.728 1.58 −1.94 −1.06 −0.45 0.33 √
PHD11 1.491 0.560 0.733 0.470 0.677 1.38 −1.33 −0.65 −0.23 0.47 √
PHD12 1.349 0.673 0.759 0.546 0.627 1.53 −1.61 −0.91 −0.33 0.33 √
PHD13 1.390 0.515 0.732 0.497 0.783 1.05 −1.84 −0.68 0.00 1.25 √
PHD14 1.305 0.807 0.711 0.481 0.666 0.77 −3.04 −1.74 −0.80 0.83 √
PHD15 1.329 0.772 0.739 0.519 0.643 0.93 −2.19 −1.68 −0.98 0.43 √
PHD16 1.553 0.766 0.833 0.744 0.931 1.23 −1.12 −0.63 −0.19 0.66 √
PHD17 1.546 0.865 0.893 0.833 0.915 1.11 −1.17 −0.64 −0.03 0.87 √
PHD18 1.679 0.836 0.873 0.794 0.922 1.29 −0.46 0.04 0.40 1.03 √
PHD19 1.663 0.888 0.913 0.857 0.910 1.27 −0.59 −0.13 0.23 0.97 √
PHD20 1.606 0.896 0.925 0.879 0.906 1.35 −0.77 −0.26 0.13 0.93 √
PSD1 1.461 0.719 0.763 0.597 0.809 0.88 −1.53 −0.37 0.20 1.86 √
PSD2 1.303 0.714 0.754 0.606 0.805 1.12 −2.21 −0.67 −0.03 1.36 √
PSD3 1.271 0.763 0.780 0.649 0.793 1.38 −1.93 −0.85 −0.26 0.99 √
PSD4 1.338 0.703 0.768 0.622 0.800 1.25 −1.54 −0.37 0.21 1.74 √
PSD5 1.296 0.756 0.806 0.684 0.783 1.50 −1.67 −0.59 −0.01 1.18 √
PSD6 1.232 0.635 0.709 0.546 0.849 1.78 −1.74 −0.84 −0.28 0.72 √
PSD7 1.225 0.507 0.786 0.656 0.821 1.65 −1.83 −0.91 −0.34 0.79 √
PSD8 1.260 0.669 0.843 0.738 0.799 1.88 −1.62 −0.81 −0.24 0.74 √
PSD9 1.302 0.742 0.806 0.676 0.816 1.93 −1.53 −0.53 −0.19 0.78 √
PSD10 1.236 0.767 0.811 0.693 0.811 2.18 −1.66 −0.75 −0.37 0.48 √
PSD11 1.229 0.556 0.808 0.649 0.730 2.07 −1.72 −0.81 −0.27 0.59 √
PSD12 1.264 0.626 0.847 0.709 0.698 2.12 −1.55 −0.73 −0.20 0.62 √
PSD13 1.352 0.647 0.758 0.544 0.783 1.28 −1.93 −0.88 −0.26 0.64 √
PSD14 1.256 0.430 0.748 0.550 0.777 1.76 −1.62 −0.87 −0.39 0.71 √
SOD1 1.486 0.797 0.885 0.745 0.914 1.28 −1.41 −0.19 −0.26 1.05 √
SOD2 1.464 0.878 0.943 0.868 0.811 1.55 −1.20 −0.25 0.25 0.96 √
SOD3 1.511 0.825 0.920 0.814 0.857 1.63 −1.13 −0.20 0.19 0.76 √
SOD4 1.560 0.744 0.848 0.688 0.784 0.22 −5.34 −3.21 −2.21 2.39 √
SOD5 1.233 0.833 0.813 0.680 0.788 0.39 −6.31 −3.12 −2.02 1.70 √
SOD6 1.510 0.790 0.852 0.704 0.774 0.28 −4.74 −2.26 −1.35 2.60 √
SOD7 1.189 0.766 0.766 0.616 0.814 0.44 −5.74 −3.72 −2.61 1.12 √
THD1 1.026 0.817 0.820 0.736 0.825 0.54 −6.29 −4.54 −1.95 0.33 √
THD 2 1.140 0.743 0.798 0.692 0.831 0.47 −6.03 −3.89 −2.11 0.73 √
Luo et al. Health and Quality of Life Outcomes  (2015) 13:53 Page 10 of 18
Table 5 Results of the second item-selection phase using CTT and IRT (Continued)
THD 3 1.252 0.666 0.711 0.549 0.861 0.33 −6.00 −2.44 1.08 4.05 X
THD 4 1.080 0.750 0.736 0.614 0.845 0.50 −6.89 −4.28 −1.91 0.59 √
THD 5 1.022 0.773 0.775 0.674 0.835 0.54 −6.19 −4.46 −2.26 0.28 √
THD 6 1.151 0.783 0.796 0.687 0.831 0.59 −5.00 −3.19 −1.31 0.79 √
Note: CTT, classical test theory; IRT, item response theory; SD, Standard Deviation; CITC, corrected item-total correlation; CAID, Cronbach’s α if item deleted ;"√"
decision to retain the selected item, "X" to delete the item; boldface indicates values that did not meet standard.
Table 6 Bank of 46 items in the final Stroke-PROM
Item Item
PHD1. Have you felt numbness in your lips or limbs? PSD4. Do you worry about your condition getting worse?
PHD2. Have you felt any limb abnormalities (such as a burning sensation)? PSD5. Have you felt upset?
PHD3. Have you felt limb weakness on just the sick side of your body? PSD6. Have you felt depressed and passionless?
PHD4. Have you had facial paralysis on one side, and saliva dripping from
your mouth?
PSD7. Have you felt frustrated, pessimistic, or in despair about your
illness?
PHD5. Have you had difficulty swallowing? PSD8. Have you felt uninterested in things and people around you?
PHD6. Have you experienced gagging while eating or drinking? PSD9. Do you consider yourself a burden on your family?
PHD7. Do your hands tremble when you reach for or pick up things? PSD10. Have you felt hopeless?
PHD8. Do you find it very difficult to focus on one thing? PSD11. Do you not want to associate with others?
PHD9. Do you have trouble remembering the date? PSD12. Do you come up with excuses to avoid social activities?
PHD10. When you see an object suddenly, do you struggle to bring its
name to mind?
PSD13. When others talk about your disease, do you prefer not to
discuss it?
PHD11. Do you have difficulty speaking (such as stammering, unclear
enunciation, or pauses)?
PSD14. Have you felt unconfident?
PHD 12. Do you need to repeat yourself to others so that they can
understand what you mean?
SOD1. Has your illness affected your family life?
PHD13. Do you remember what happened two days ago? SOD2. Have you reduced contact with your acquaintances and friends
due to your illness?
PHD14. Can you understand what others are saying? SOD3. Have you avoided some social or family activities due to your
illness?
PHD15. Can you recall your children’s or parents’ names? SOD4. Is your family taking care of your daily life needs?
PHD16. Can you twist a door handle to open the door by yourself? SOD5. Have your relatives and friends expressed concern about your
condition?
PHD17. Can you take care of your own daily needs (such as dressing and
bathing)?
SOD6. Has your family reminded you to take your medicine?
PHD18. Can you purchase your daily necessities alone (for example, by
going shopping)?
SOD7. Does your family understand you?
PHD19. Can you walk up and down stairs alone? THD1. Are you satisfied with the current effects of your treatment?
PHD20. Can you do light housework (such as making your bed)? THD2. Are you satisfied with the medical treatment service you
receive?
PSD1. Are you more prone to worry since your illness? THD3. Has treatment at this stage had the effect of reducing your
symptoms?
PSD2. Do you struggle to be patient with others? THD4. Would you like to continue to maintain your current treatment
schedule?
PSD3. Do you often feel nervous? THD5. Has your overall confidence improved since you have been
receiving treatment?
Note: PHD, physical domain; PSD, psychological domain; SOD, social domain; THD, therapeutic domain.
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NFI, NNFI, CFI, IFI) met the standard requirements
(see Table 9).
Table 10 presents the 10 subdomains, their corre-
sponding items and standardized factor loadings pro-
duced from the CFA. The standardized factor loadings
for each of the 46 Stroke-PROM items were above 0.5,
except for items PHD1, PHD2, and PHD3; however,
these three items were recommended for retention by
the results of CTT and IRT analyses. The results indi-
cated that the 46 items showed salient loadings on
their specific subdomains, and these 10 subdomains
correlated well with the 10 that were conceptualized
in the design phase and indicated good construct
validity.
Reliability
Cronbach’s α coefficient ≥0.70 is considered acceptable
for internal consistency. Cronbach’s α coefficient was
0.905 for the total score, and for the four domains, it
ranged from 0.861 to 0.908. These results indicated high
internal consistency (see Table 11).
Table 7 Scale structure of the bank of 46 items of the final Stroke-PROM
Domain Subdomain Item
Physical domain (PHD) Somatic symptom (SOS) 1-, 2-, 3-, 4-, 5-, 6-, 7-
Cognition (COG) 8-, 9-, 10-, 13
Verbal communication (VEC) 11-, 12-, 14, 15
Self-help skills (SHS) 16, 17, 18, 19, 20
Psychological domain (PSD) Anxiety (ANX) 1-, 2-, 3-, 4-, 5-
Depression (DEP) 6-, 7-, 8-, 9-, 10-
Avoidance (AVO) 11-, 12-, 13-, 14-
Social domain (SOD) Social contacts (SOC) 1-, 2-, 3-
Family support (FAS) 4, 5, 6, 7
Therapeutic domain (THD) Satisfaction (SAT) 1, 2, 3, 4, 5
Note: “-” indicates a reverse-scored item.
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Number of
domains
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— 7 (PHD3, PHD5, PHD6, PHD9, PHD16, PSD18,
SOD1 of Additional file 1: Appendix 1-1)
13 (PHD18, PHD19, PSD2, PSD5, PSD8, PSD9, PSD15,
PSD20, SOD1, SOD2, THD1, THD2, THD3 of Additional








— I-CVI (PHD3, PHD5, PHD6, PHD9, SOD1);
Opinions of patients and clinical experts,
reference to other scales (PHD16, PSD18)
CTT and IRT (PHD18, PHD19, PSD5, PSD8, PSD9, PSD20,
SOD1, SOD2, THD1); IRT, opinions of patients and
clinical experts, reference to other scales (THD2, THD3);
Opinions of patients and clinical experts, reference to






— 5 (PHD2, PHD7, PHD10, PHD11, PSD18 of






— Opinions of patients and clinical experts,
reference to other scales
— —
Note: PHD, physical domain; PSD, psychological domain; SOD, social domain; THD, therapeutic domain.
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Discriminant validity
The discriminant validity of each subdomain was exam-
ined by comparing mean scores across healthy partici-
pants and the groups of stroke patients as defined by
their modified Rankin scores. Table 12 indicates that the
scales for 9 of the 10 subdomains were significantly dif-
ferent across healthy participants and stroke patients
with different degrees of disability and dependence as
defined by the modified Rankin scale. Because healthy
participants were not treated and therefore could not
answer the items in the treatment domain, no compari-
son of healthy participants was made for the SAT subdo-
main. However, the SAT subdomain scores for the
stroke patient population was not significantly different
across the Rankin levels. Overall, the Stroke-PROM was
able to differentiate between healthy participants and
stroke patients with varying degrees of disability and
dependence as defined by the modified Rankin scale.
Feasibility
Both the response rate and the completion rate of the
Stroke-PROM tool were more than 97%. The average
completion time was 8.9 minutes.
Discussion
In this study, we developed and validated a Stroke-
PROM for use in the evaluation of outcomes for patients
with stroke. The US Food and Drug Administration
(FDA) has highlighted the importance of the use of
PRO in clinical trials and provided guidance regarding
the development of PROMs [24]. The development
strategy for the Stroke-PROM in this study complied
with those guidelines. To the best of our knowledge,
this is the first Stroke-PROM specifically developed and
validated for use in clinical trials of new drugs with
stroke to include physical, psychological, social and
therapeutic domains [25].
The most commonly used stroke-specific measures,
the National Institutes of Health Stroke Scale and the
Canadian Neurological Scale are clinician-reported
outcome measures that assess only the physical aspects
of stroke [26-28]. Although the Stroke Impact Scale
Version 2.0, the Stroke and Aphasia Quality of Life
Scale-39, the Newcastle Stroke-Specific Quality of Life
Measure, and the Stroke-Specific Quality of Life mea-
sures are all multidimensional PRO measures, no mea-
sures have been developed that assess the subdomains
of family support and patient satisfaction with treat-
ment [13-15,29]. In contrast to other stroke-specific in-
struments, our instrument includes these subdomains
and therefore fills a gap in the research arena for a
stroke PROM [13-15,29-31].
Stroke has considerable adverse physical and psycho-
logical impacts on patients over time. Stroke patients
need help, understanding and care from their families
[32]. Indeed, a growing body of research demonstrates
the importance of family relationships for the recovery
of functional capacity after stroke [33,34]. A stroke sur-
vivor’s family is often the most important source of
long-term support during the patients’ recovery and
treatment, and family support plays a significant role
throughout the poststroke recovery period [35-38]. Fam-
ily can supply the stroke survivor with physical and
mental support, such as providing care in daily life and
understanding [39]. Therefore, family support is a neces-
sary addition to the Stroke-PROM.
Satisfaction with treatment is a main outcome measure
in new drug clinical trials [24,40]. A Stroke-PROM tool
can be used to measure treatment benefit or risk during
clinical trials for medical products. Additionally, Stroke-
PROM instruments provide optimal information from
the patient’s perspective for use in drawing conclu-
sions about the effectiveness of treatment [24]. Thus,
the inclusion of a subdomain for treatment satisfac-
tion provides an opportunity for new drug clinical trial
participants to integrate into the overall evaluation
the different aspects of their responses to treatment,
including pain relief, function improvement, and side
effects, as well as to provide feedback about the
potential acceptability of a new drug and their overall
trust in the drug treatment [24,41,42]. Therefore, the
subdomain of satisfaction with treatment is also a
prudent addition to the Stroke-PROM.
The Stroke-PROM presented here would complement
existing stroke-specific measures and has particular
value for extending our understanding of the impact of
family support and patient satisfaction with treatment in
clinical trials of new drugs for stroke. During clinical tri-
als, the Stroke-PROM can be used to simultaneously
measure the effect of a medical intervention on several
concepts, that is, the measured parameter, such as a
symptom or group of symptoms, the medical interven-
tion effects on a particular function or group of func-
tions, or a group of symptoms or functions shown to
measure the severity of a health condition. The use of
the Stroke-PROM as an outcome measure in clinical
trials may facilitate evaluation of the effectiveness across
Table 9 Goodness of fit statistics of the Stroke-PROM
Domain GFI RMR NFI NNFI CFI IFI
PHD 0.79 0.086 0.88 0.88 0.90 0.90
PSD 0.89 0.058 0.95 0.95 0.96 0.96
SOD 0.90 0.092 0.92 0.88 0.93 0.93
THD 0.94 0.043 0.95 0.91 0.96 0.96
Note: PHD, physical domain; PSD, psychological domain; SOD, social domain;
THD, therapeutic domain; GFI, goodness-of-fit index; NFI, normed fit index;
NNFI, non-normed fit index; IFI, incremental fit index; CFI, comparative fit
index; RMR, root mean square residual.
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SOS PHD1 0.67 0.07 9.40 0.20 1.87 0.44 0.80
PHD2 0.56 0.07 8.05 0.15 1.83 0.38 0.85
PHD3 0.67 0.07 9.25 0.19 1.93 0.44 0.81
PHD4 0.89 0.06 15.17 0.44 1.02 0.66 0.56
PHD5 1.01 0.05 20.25 0.67 0.50 0.82 0.33
PHD6 0.93 0.05 18.25 0.58 0.62 0.76 0.42
PHD7 0.84 0.06 14.91 0.43 0.96 0.65 0.57
COG PHD8 0.93 0.06 16.79 0.53 0.77 0.73 0.47
PHD9 0.94 0.06 16.50 0.51 0.84 0.72 0.49
PHD10 0.92 0.05 17.38 0.56 0.67 0.75 0.44
VEC PHD11 1.02 0.07 15.41 0.47 1.18 0.68 0.53
PHD12 1.02 0.06 17.35 0.57 0.79 0.75 0.43
COG PHD13 0.82 0.06 12.96 0.35 1.25 0.59 0.65
VEC PHD14 0.65 0.06 10.49 0.25 1.28 0.50 0.75
PHD15 0.71 0.06 11.37 0.28 1.27 0.53 0.72
SHS PHD16 1.17 0.06 19.09 0.57 1.04 0.76 0.43
PHD17 1.30 0.06 22.31 0.70 0.71 0.84 0.30
PHD18 1.40 0.06 22.10 0.69 0.86 0.83 0.31
PHD19 1.52 0.06 25.72 0.84 0.45 0.91 0.16
PHD20 1.50 0.06 26.74 0.87 0.33 0.93 0.13
ANX PSD1 0.90 0.06 14.01 0.38 1.32 0.62 0.62
PSD2 0.83 0.06 14.45 0.40 1.02 0.63 0.60
PSD3 0.92 0.05 17.14 0.52 0.77 0.72 0.48
PSD4 0.99 0.06 17.74 0.55 0.81 0.74 0.45
PSD5 1.04 0.05 19.85 0.64 0.60 0.80 0.36
DEP PSD6 0.79 0.05 14.88 0.41 0.89 0.64 0.59
PSD7 0.87 0.05 17.05 0.51 0.74 0.71 0.49
PSD8 1.02 0.05 20.57 0.66 0.54 0.81 0.34
PSD9 0.96 0.05 18.02 0.55 0.77 0.74 0.45
PSD10 0.95 0.05 18.88 0.59 0.63 0.77 0.41
AVO PSD11 0.97 0.05 19.25 0.62 0.57 0.79 0.38
PSD12 1.04 0.05 20.31 0.67 0.53 0.82 0.33
PSD13 0.81 0.06 13.53 0.36 1.17 0.60 0.64
PSD14 0.80 0.06 14.56 0.41 0.93 0.64 0.59
SOC SOD1 1.16 0.06 19.83 0.61 0.86 0.78 0.39
SOD2 1.40 0.05 26.97 0.92 0.17 0.96 0.08
SOD3 1.33 0.06 23.42 0.77 0.53 0.88 0.23
FAS SOD4 1.27 0.06 19.81 0.66 0.82 0.81 0.34
SOD5 0.88 0.05 16.63 0.51 0.75 0.71 0.49
SOD6 1.23 0.06 19.83 0.66 0.77 0.81 0.34
SOD7 0.77 0.05 14.67 0.42 0.82 0.65 0.58
SAT THD1 0.83 0.04 20.28 0.66 0.36 0.81 0.34
THD2 0.81 0.05 16.69 0.50 0.65 0.71 0.50
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several therapeutic modalities. From the researcher’s
perspective, the scale may capture the patient’s experi-
ence and treatment benefit or risk, assist researchers in
determining which patients with stroke benefit meaning-
fully from treatment, and facilitate between-trial com-
parisons [24]. From the pharmaceutical company’s
perspective, such an instrument may increase the effi-
ciency of discussions with the FDA during the medical
product development process, and provide optimal in-
formation from a patient’s perspective for use in making
conclusions about treatment effects at the time of med-
ical product approval [24]. From a regulatory perspec-
tive, the Stroke-PROM tool may provide a standardized
method for assessing treatment effectiveness on basic
symptoms so that claims can be supported with PRO
evidence in medical product clinical trials [43].
In contrast to the development of other stroke-specific
instruments, our study used I-CVI, IRT and CFA as
rigorous evidence for item selection, validity and reliabil-
ity. First, content validity is an essential step in the de-
velopment of any new scale. None of the previously
developed instruments for stroke used statistical
methods such as CVI to quantify content validity as was
done for the Stroke-PROM tool in our study. The FDA
places particular emphasis on demonstrating content
validity using open-ended interviews with patients [24].
Identifying the items of the Stroke-PROM based on a
review of the literature and other stroke questionnaires,
face-to-face interviews with patients, discussions with
stroke professionals and the CVI further strengthened
the content validity of the preliminary scale in our study.
Second, in the item-selection phase, analyses based on
both CTT and IRT were used to delete items. The IRT-
based analysis was used more heavily than that based on
CTT in the construction of scales for measuring subject-
ive attributes. IRT-based analysis also afforded more
accurate examinations of the features of each scale item
than the analyses based on CTT. Existing stroke-specific
instruments had focused exclusively on CTT statistics
(e.g., exploratory factor analysis, Cronbach’s α coeffi-
cient) [13,29]. No other stroke-specific instruments
existed that had been developed using IRT. CTT statis-
tics are associated with certain disadvantages, whereas
methods based on IRT offer several advantages to refine
items and therefore to improve on CTT [44].
In our study, both CTT and IRT analyses were re-
peated during finalization of the item content in the
second sample. The results showed that the final
Stroke-PROM had a high degree of reliability and
validity.
Third, the instrument’s presumed internal structure,
supported by CFA, confirmed that the Stroke-PROM
measure is multidimensional in nature. No other stroke-
specific instruments have established construct validity
with CFA.
In summary, our results showed that the scale was
valid, reliable and feasible and had strong discriminative
properties between healthy controls and stroke patients
with varying degrees of disability and dependence as
defined by the modified Rankin scale. Although the
Stroke-PROM tool was developed primarily for use in
clinical trials of new drugs to evaluate their clinical
therapeutic effects, this study showed that the Stroke-
PROM also had strong discriminative measurement
properties and could be used to differentiate patients
with stroke from healthy controls. We therefore believe
that there is an important role for this Stroke-PROM
instrument in clinical practice as well as in clinical trials.
Limitations and further development
The scale has several potential limitations that we will
address in future studies.
First, in the evaluation of validity, our study did not
explicitly address criterion validity. Most of the patients
with stroke were elderly, and completion of two or more
scales would have been a significant burden for them,
according to our experts on stroke. Stroke patients often
experience disturbances of consciousness and physical
restlessness; thus, adding more tests could produce test
fatigue in these patients, thereby reducing the validity
and reliability of measurement. Therefore, instead of
asking patients to complete more than one scale, we
Table 10 Maximum likelihood estimation of CFA for the Stroke-PROM (Continued)
THD4 0.78 0.05 17.08 0.52 0.56 0.72 0.48
THD5 0.77 0.04 18.22 0.57 0.45 0.75 0.43
THD6 0.85 0.05 17.71 0.55 0.60 0.74 0.45
Note: PHD, physical domain; PSD, psychological domain; SOD, social domain; THD, therapeutic domain; SOS, somatic symptom; COG, cognition; VEC, verbal
communication; SHS, self-help skills; ANX, anxiety; DEP, depression; AVO, avoidance; SOC, social contacts; FAS, family support; COM, compliance; SAT, satisfaction.
Table 11 Cronbach’s α coefficient of four domains and
total scale
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chose to delay a thorough examination of criterion valid-
ity for a future investigation.
Second, test–retest reliability was not measured as part
of the validation process. This was due in part to the
additional burden it would have placed on patients, but
also because of the difficulties inherent in follow-up with
patients in their home communities and rural areas. We
therefore demonstrated reliability only with internal
consistency; however, we conducted our reliability evalu-
ation of items at two points in the process: during the
phases of item selection and scale evaluation.
Third, the stroke patient sample differed slightly from
the healthy participant sample in two ways: the stroke
patient population had a higher proportion of males and
of individuals over 65 years old. Future studies should
seek to balance these groups.
Because of limited resources (both funding and
personnel), the sample populations may not be represen-
tative of the entire population of patients with stroke.
Our participants were from only the Shanxi province in
northern China. Thus, future studies should evaluate
reliability and validity of the Stroke-PROM instrument
with a nationwide sample.
The Stroke-PROM was administered to native-Chinese-
speaking individuals. Therefore, further work is required
to test the strengths and weaknesses of this instrument
across various national, cultural and language contexts.
Conclusions
Our results provided evidence for satisfactory reliability
and validity of the Stroke-PROM. However, the instru-
ment will require additional revisions and improvements
through testing in different populations. The ongoing
process of modifying the Stroke-PROM will also
encompass further validation and reliability testing
across various applications of the instrument. The
Stroke-PROM is not meant to replace existing stroke-
specific measures, but to provide further valuable infor-
mation on patients with stroke. This innovative instru-
ment may be helpful in both routine medical practice and
clinical research.
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Table 12 Subdomain scores obtained using the Stroke-PROM instrument in healthy controls and stroke patients with
varying degrees of disability and dependence as defined by the modified Rankin scale (mean ± SD)
Sub-
domain
Control Rankin level F P
0 1 2 3 4 5
SOS 32.95 ± 3.02 27.90 ± 6.57 26.31 ± 6.20 24.85 ± 6.30 24.53 ± 6.35 25.98 ± 4.96 23.46 ± 6.96 25.652 <0.001
COG 19.33 ± 2.27 16.59 ± 3.80 15.69 ± 3.78 13.32 ± 3.32 13.33 ± 3.38 13.86 ± 3.31 13.42 ± 4.79 32.806 <0.001
VEC 19.43 ± 1.98 17.96 ± 3.09 16.45 ± 3.26 14.22 ± 2.82 12.54 ± 3.37 13.81 ± 3.00 12.62 ± 4.51 59.779 <0.001
SHS 23.61 ± 3.03 24.33 ± 1.59 19.39 ± 3.16 15.68 ± 2.03 12.19 ± 2.33 8.91 ± 1.94 5.59 ± 1.26 769.629 <0.001
ANX 22.85 ± 2.90 17.61 ± 5.03 17.55 ± 5.31 17.34 ± 4.31 16.88 ± 4.51 16.07 ± 5.17 15.93 ± 5.86 21.911 <0.001
DEP 24.11 ± 2.11 21.04 ± 4.26 19.09 ± 4.71 18.44 ± 4.30 17.83 ± 4.90 17.45 ± 5.13 17.87 ± 5.71 25.407 <0.001
AVO 19.36 ± 1.75 16.79 ± 3.38 15.29 ± 3.89 14.00 ± 3.89 14.10 ± 3.43 14.26 ± 4.02 14.70 ± 4.97 24.756 <0.001
SOC 14.49 ± 1.55 11.88 ± 3.87 9.03 ± 4.09 9.63 ± 2.95 9.95 ± 3.61 9.48 ± 3.70 8.72 ± 4.43 31.575 <0.001
FAS 8.76 ± 4.72 14.27 ± 4.82 14. 90 ± 3.95 15.12 ± 4.95 14.33 ± 4.35 15.48 ± 4.49 16.25 ± 4.56 28.217 <0.001
SAT – 24.19 ± 4.83 24.30 ± 4.32 22.90 ± 6.23 23.35 ± 5.61 21.88 ± 5.99 24.03 ± 5.40 1.929 >0.050
n 104 135 123 41 58 42 76
Note: SOS, somatic symptom; COG, cognition; VEC, verbal communication; SHS, self-help skills; ANX, anxiety; DEP, depression; AVO, avoidance; SOC, social contacts;
FAS, family support; SAT, satisfaction.
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